Asunto(s)
Aneurisma/diagnóstico , Venas Yugulares/patología , Cuello/patología , Trombosis de la Vena/diagnóstico , Adulto , Aneurisma/complicaciones , Aneurisma/tratamiento farmacológico , Aneurisma/patología , Anticoagulantes/uso terapéutico , Traumatismos en Atletas/complicaciones , Traumatismos en Atletas/diagnóstico , Traumatismos en Atletas/tratamiento farmacológico , Diagnóstico Diferencial , Edema/diagnóstico , Edema/tratamiento farmacológico , Edema/patología , Humanos , Venas Yugulares/diagnóstico por imagen , Masculino , Cuello/diagnóstico por imagen , Traumatismos del Cuello/complicaciones , Traumatismos del Cuello/diagnóstico , Traumatismos del Cuello/tratamiento farmacológico , Dolor de Cuello/diagnóstico , Dolor de Cuello/tratamiento farmacológico , Dolor de Cuello/etiología , Trombosis de la Vena/complicaciones , Trombosis de la Vena/tratamiento farmacológico , Trombosis de la Vena/patologíaAsunto(s)
Brazo/patología , Hemangiosarcoma/diagnóstico , Linfangiosarcoma/diagnóstico , Enfermedades de la Piel/diagnóstico , Enfermedades de la Piel/patología , Anciano de 80 o más Años , Diagnóstico Diferencial , Femenino , Hemangiosarcoma/patología , Humanos , Linfangiosarcoma/patología , Linfedema/complicaciones , Linfedema/patología , Enfermedades de la Piel/complicacionesRESUMEN
INTRODUCTION: While in most countries warfarin is the preferred anti-vitamin K, fluindione, a molecule with a prolonged half-life remains largely prescribed in France. Some of its side effects, including immuno-allergic complications, remain poorly understood. CASE REPORT: A 77-year-old woman presented with a febrile severe neutropenia of immunoallergic mechanism with a favourable outcome associated with fluindione, introduced 25 days earlier for the treatment of atrial fibrillation. CONCLUSION: This rare side effect is a reminder of the importance of biological monitoring in the first weeks following the introduction of fluindione and key diagnostic elements and therapeutic aspects of iatrogenic agranulocytosis.
Asunto(s)
Agranulocitosis/inducido químicamente , Anticoagulantes/efectos adversos , Fenindiona/análogos & derivados , Anciano , Agranulocitosis/patología , Neutropenia Febril Inducida por Quimioterapia/patología , Hipersensibilidad a las Drogas/patología , Femenino , Francia , Humanos , Fenindiona/efectos adversosRESUMEN
PURPOSE: More than one million patients received an oral anticoagulant treatment in France. This medication is the first aetiology of iatrogenic events. Recently, direct oral anticoagulant (DOA) provided efficacy and safety in the treatment of atrial fibrillation and venous thromboembolic events. Given the growing increase in the prescription of these molecules, with many advantages but also disadvantages, it seemed interesting to assess in routine hospital medical practice, the proportion of patients for which the initiation of AOD could be safe. METHODS: This prospective, observational study was conducted in the department of internal medicine from October 2012 and September 2013. All inpatients receiving oral anticoagulant treatment have been included. Demographic data, indication of anticoagulant treatment, contraindications and interactions have been reported. From these information, we have established the percentage of patients who could benefit from DOA safely and securely. RESULTS: Two hundred and ninety inpatients were included with a mean age of 76.3±15.2 years old. Atrial fibrillation and thromboembolic venous disease were the most prevalent indications of anticoagulant treatments (67.2% and 22.4% of cases respectively). Among all patients, 260 had an indication of DOA (89.7%), authorized by the French National health agency. Eighty percent had both indication and no contraindication for DOA. However, only 53.1% of patients neither had drug-drug interaction. Main contraindications were severe renal failure (clearance<30mL/min) in 10.7% of cases, and recent history of gastric ulcer in 15.3% of cases. The most frequent interactions with DOA were antiplatelet agent (14.5%) and amiodarone (11.6%). Almost two thirds of inpatients (65.1%) had at least one drug-drug interaction with VKA. CONCLUSION: These results, coming from "real life", provide that only 53.1% of inpatients under anticoagulants could receive DOA safely. Caution is warranted, and VKA still have a preponderant role among anticoagulant drugs.
Asunto(s)
Anticoagulantes/administración & dosificación , Tromboembolia/prevención & control , Administración Oral , Anciano , Fibrilación Atrial/complicaciones , Femenino , Humanos , Masculino , Estudios Prospectivos , Tromboembolia/etiología , Vitamina K/antagonistas & inhibidoresRESUMEN
INTRODUCTION: Venous thromboembolism and dehydration are frequent conditions in elderly. The objective of this study was to assess the prevalence of dehydration in patients aged over 70 years suspected of deep vein thrombosis (DVT). METHODS: This is a prospective observational study that included patients aged over 70 years and suspected of deep vein thrombosis. Clinical and biological dehydration was diagnosed on the presence of a skin fold, a weight loss≥5%, a thirst, a plasmatic osmolality>295 mOsm/L or blood urea nitrogen/creatinine ratio>20. RESULTS: One hundred and forty-four patients (mean age 81.8±5.8 years) were included. A diagnosis of DVT was retained in 97 patients. Clinical dehydration was not more frequent in the DVT+ group (37.2% vs 35.1%). At baseline, 69.1% of DVT+ patients and 53.2% of DVT- patients had a plasma osmolality greater than 295 mosm/L (NS). BUN/creatinine ratio greater than 20 was found in 58.8% of DVT+ patients and 72.3% of DVT- patients (NS). Clinical and biological dehydration was present in 28.6% of DVT+ patients and in 33.3% of DVT- patients (NS). The positive predictive value of the Wells score≥3 was 86.5%, and negative predictive value of a Wells score≤0 was 85%. CONCLUSION: The presence of dehydration does not appear predictive of the occurrence of DVT and does not influence the statistical performance of the Wells score in elderly patients.